Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT ID: NCT04509700
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
112 participants
INTERVENTIONAL
2020-08-03
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT04809467
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02760485
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
NCT02018861
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
NCT02998476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
parsaclisib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Parsaclisib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
parsaclicib + itacitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + itacitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + ruxolitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
parsaclisib + ruxolitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
parsaclisib + ibrutinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + ibrutinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Parsaclisib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + itacitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + ruxolitinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
parsaclisib + ibrutinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently tolerating treatment in the parent Protocol.
* Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator.
* Has at least stable disease, as determined by the investigator.
* Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
* Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol.
* Willingness to avoid pregnancy or fathering children
* Ability to comprehend and willingness to sign an ICF
Exclusion Criteria
* Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study.
* Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
* Pregnant or breastfeeding women.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uab Comprehensive Cancer Center
Birmingham, Alabama, United States
University of Alabama At Birmingham
Birmingham, Alabama, United States
Mayo Clinic Rochester
Phoenix, Arizona, United States
University of Arizona Cancer Center-Out Pt.
Tucson, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
California Cancer Associates For Research and Excellence
Fresno, California, United States
Innovative Clinical Research Institute
Long Beach, California, United States
Rocky Mountain Cancer Center
Aurora, Colorado, United States
Rush University Medical Center-Consultants in Hematology
Chicago, Illinois, United States
University of Kansas Hospital Authority
Westwood, Kansas, United States
Rcca Md, Llc
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Cancer Center
Ann Arbor, Michigan, United States
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi, United States
Saint Luke'S Hospital of Kansas City
Kansas City, Missouri, United States
Hca Midwest Health-Research Medical Center
Kansas City, Missouri, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University Hospitals Case Medical Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University
Columbus, Ohio, United States
Knight Cancer Institute At Oregon Health and Science University
Portland, Oregon, United States
Baylor Scott White Univeristy Medical Center
Dallas, Texas, United States
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington, United States
Medical University of Vienna
Vienna, , Austria
Cliniques Universitaires Ucl Saint-Luc
Brussels, , Belgium
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, , Belgium
Az Groeninge
Kortrijk, , Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, , Belgium
University Hospital Hradec Kralove
Hradec Králové, , Czechia
Univerzita Karlova V Praze 1. Lekarska Fakulta
Prague, , Czechia
Fakultni Nemocnice V Motole
Prague, , Czechia
University Hospital Kralovkse Vinohrady
Prague, , Czechia
Aarhus University Hospital
Århus N, , Denmark
Rigshospitalet
Copenhagen, , Denmark
Sjaellands Universitetshospital
Roskilde, , Denmark
Chru de Brest Hospital Morvan
Brest, , France
Centre Antoine Laccassagne
Nice, , France
Ap-Hp Groupe Hospitalier Saint-Louis Lariboisiere Fernand-Widal Site Saint Louis (Paris)
Paris, , France
Hospital Universitaire Pitie-Salpetriere
Paris, , France
Centre Hospitalier Universitaire de Toulouse
Toulouse, , France
Chru Hopitaux de Tours Hospital Bretonneau
Tours, , France
Petz Aladar County Teaching Hospital
Győr, , Hungary
Hadassah Hebrew University Medical Center Ein Karem Hadassah
Jerusalem, , Israel
Rabin Medical Center - Beilinson Hospital
Petah Tikva, , Israel
Sheba Medical Center
Tel Litwinsky, , Israel
University of Bologna Institute of Haematology L E A Seragnoli
Bologna, , Italy
Lstituto Di Ematologia Lorenzo Ea.Seragnoli Universita Degli Studi Di Bologna - Policlinico S. Or
Bologna, , Italy
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, , Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori
Meldola (FC), , Italy
Fondazione Irccs Ca Granda Ospedale Maggiore
Milan, , Italy
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
Milan, , Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, , Italy
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
Milan, , Italy
Universita Di Napoli Federico Ii
Naples, , Italy
Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara
Novara, , Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
Palermo, , Italy
Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara
Pisa, , Italy
Ospedale Santa Maria Delle Croci
Ravenna, , Italy
Ospedale Sant. Eugenio
Roma, , Italy
Juntendo University Hospital
Bunkyō City, , Japan
National Cancer Center Hospital
Chūō, , Japan
Kansai Medical University Hospital
Hirakata, , Japan
Tokai University Hospital
Isehara, , Japan
Irb of Kobe City Medical Center General Hospital
Kobe, , Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, , Japan
Nho Matsumoto Medical Center
Matsumoto-shi, , Japan
Miyagi Cancer Center
Miyagi, , Japan
Jrc Aichi Medical Center Nagoya Daini Hospital
Nagoya, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Osaka Metropolitan University Hospital
Osaka, , Japan
Hokuyukai Sapporo Hokuyu Hospital
Sapporo, , Japan
National Hospital Org. Hokkaido Cancer Center
Sapporo, , Japan
Tohoku University Hospital
Sendai, , Japan
Tokyo Medical University Hospital
Shinjuku, , Japan
Tenri Hospital
Tenri, , Japan
Nippon Medical School Hospital
Tokyo, , Japan
Yokohama Municipal Citizens Hospital
Yokohama, , Japan
University of Fukui Hospital
Yoshida-gun, , Japan
Haukeland University Hospital
Bergen, , Norway
Sp Zoz Szpital Uniwersytecki
Kracow, , Poland
Wwcoit Im. M. Kopernika W Lodzi
Lodz, , Poland
Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
Nowy Sącz, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Wroclaw, , Poland
The Catholic University of Korea Seoul St. Mary'S Hospital
Seoul, , South Korea
Hospital General Unviersitario de Alicante
Alicante, , Spain
Germans Trias I Pujol
Badalona, , Spain
Hospital Del Mar
Barcelona, , Spain
Hospital Clinic Barcelona
Barcelona, , Spain
Hospital Clinic I Provincial
Barcelona, , Spain
Start Madrid - Ciocc
Boadilla del Monte, , Spain
Institut Catala Doncologia - Hospital Duran I Reynals
L'Hospitalet de Llobregat, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Hospital Universitario Fundacin Jimnez Daz
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario Hm Sanchinarro
Madrid, , Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, , Spain
Hospital Clinico Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Karolinska University Hospital Solna
Stockholm, , Sweden
Istanbul Medipol Universitesi Ibagcilar Medipol Mega Universitesi Hastanesi
Istanbul, , Turkey (Türkiye)
Ege University Hospital
Izmir, , Turkey (Türkiye)
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-501687-18-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2019-004948-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
INCB 50465-801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.